Osteopontin expression is essential for interferon-α production by plasmacytoid dendritic cells

Nature Immunology

Volumn 7, Issue 5, 2006, Pages 498-506

  Shinohara, Mari L ^a,b   Lu, Linrong ^a,b   Bu, Jing ^a,b   Werneck, Miriam B F ^a,b   Kobayashi, Koichi S ^a,b   Glimcher, Laurie H ^a,b   Cantor, Harvey ^a,b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON REGULATORY FACTOR 7; MYELOID DIFFERENTIATION FACTOR 88; OSTEOPONTIN; TOLL LIKE RECEPTOR 9; TRANSCRIPTION FACTOR T BET;

ANIMAL CELL; ARTICLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CPG ISLAND; CROSS PRESENTATION; CYTOKINE PRODUCTION; DENDRITIC CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPRESSION VECTOR; GENE EXPRESSION; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; IMMUNOPRECIPITATION; IN VITRO STUDY; LYMPHOCYTE SUBPOPULATION; MOLECULAR MECHANICS; MOUSE; NATURAL KILLER CELL; NONHUMAN; PLASMA CELL; PRIORITY JOURNAL; PROTEIN LOCALIZATION; REAL TIME POLYMERASE CHAIN REACTION; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

ANIMALS; CELL LINE; CPG ISLANDS; CROSS-PRIMING; DENDRITIC CELLS; HUMANS; INTERFERON-ALPHA; KILLER CELLS, NATURAL; MICE; MICE, KNOCKOUT; MYELOID CELLS; OSTEOPONTIN; SIALOGLYCOPROTEINS; T-BOX DOMAIN PROTEINS; TRANSCRIPTION FACTORS;

EID: 33645963170     PISSN: 15292908     EISSN: 15292916     Source Type: Journal    
DOI: 10.1038/ni1327     Document Type: Article

References (60)

1. Iwasaki, A. & Medzhitov, R. Toll-like receptor control of the adaptive immune responses. Nat. Immunol. 5, 987-995 (2004).
2. Liu, Y.J. IPC: Professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu. Rev. Immunol. 23, 275-306 (2005).
3. Krug, A. et al. TLR9-dependent recognition of MCMV by IPC and DC generates coordinated cytokine responses that activate antiviral NK cell function. Immunity 21, 107-119 (2004).
4. Colonna, M., Trinchieri, G. & Liu, Y.J. Plasmacytoid dendritic cells in immunity. Nat. Immunol. 5, 1219-1226 (2004).
5. Banchereau, J., Pascual, V. & Palucka, A.K. Autoimmunity through cytokine-induced dendritic cell activation. Immunity 20, 539-550 (2004).
6. Theofilopoulos, A.N., Baccala, R., Beutler, B. & Kono, D.H. Type I interferons (α/β) in immunity and autoimmunity. Annu. Rev. Immunol. 23, 307-336 (2005).
7. + T cells stimulated by virus-induced type I interferon. Nat. Immunol. 4, 1009-1015 (2003).
8. Boonstra, A. et al. Flexibility of mouse classical and plasmacytoid-derived dendritic cells in directing T helper type 1 and 2 cell development: Dependency on antigen dose and differential toll-like receptor ligation. J. Exp. Med. 197, 101-109 (2003).
9. Salio, M., Palmowski, M.J., Atzberger, A., Hermans, I.F. & Cerundolo, V. CpG-matured murine plasmacytoid dendritic cells are capable of in vivo priming of functional CD8 T cell responses to endogenous but not exogenous antigens. J. Exp. Med. 199, 567-579 (2004).
10. Honda, K., Yanai, H., Takaoka, A. & Taniguchi, T. Regulation of the type I IFN induction: A current view. Int. Immunol. 17, 1367-1378 (2005).
11. Kawai, T. & Akira, S. Pathogen recognition with Toll-like receptors. Curr. Opin. Immunol. 17, 338-344 (2005).
12. Honda, K. et al. Spatiotemporal regulation of MyD88-IRF7 signalling for robust type-I interferon induction. Nature 434, 1035-1040 (2005).
13. Ashkar, S. et al. Eta-1 (osteopontin): An early component of Type 1 (cell-mediated) immunity. Science 287, 860-864 (2000).
14. Shinohara, M.L. et al. T-bet-dependent expression of osteopontin contributes to T cell polarization. Proc. Natl. Acad. Sci. USA 102, 17101-17106 (2005).
15. Miyazaki, T. et al. Implication of allelic polymorphism of osteopontin in the development of lupus nephritis in MRL/lpr mice. Eur. J. Immunol. 35, 1510-1520 (2005).
16. Nau, G.J. et al. Attenuated host resistance against Mycobacterium bovis BCG infection in mice lacking osteopontin. Infect. Immun. 67, 4223-4230 (1999).
17. Sibalic, V., Fan, X., Loffing, J. & Wuthrich, R.P. Upregulated renal tubular CD44, hyaluronan, and osteopontin in kdkd mice with interstitial nephritis. Nephrol. Dial. Transplant. 12, 1344-1353 (1997).
18. Yu, X.Q. et al. A functional role for osteopontin in experimental crescentic glomerulonephritis in the rat. Proc. Assoc. Am. Phys. 110, 50-64 (1998).
19. Hudkins, K.L. et al. Osteopontin expression in human crescentic glomerulonephritis. Kidney Int. 57, 105-116 (2000).
20. Steinman, L., Martin, R., Bernard, C., Conlon, P. & Oksenberg, J.R. Multiple sclerosis: Deeper understanding of its pathogenesis reveals new targets for therapy. Annu. Rev. Neurosci. 25, 491-505 (2002).
21. Xu, G. et al. Role of osteopontin in amplification and perpetuation of rheumatoid synovitis. J. Clin. Invest. 115, 1060-1067 (2005).
22. Comabella, M. et al. Plasma osteopontin levels in multiple sclerosis. J. Neuroimmunol. 158, 231-239 (2005).
23. Gravallese, E.M. Osteopontin: A bridge between bone and the immune system. J. Clin. Invest. 112, 147-149 (2003).
24. Zohar, R. et al. Intracellular osteopontin is an integral component of the CD44-ERM complex involved in cell migration. J. Cell. Physiol. 184, 118-130 (2000).
25. Suzuki, K. et al. Colocalization of intracellular osteopontin with CD44 is associated with migration, cell fusion, and resorption in osteoclasts. J. Bone Miner. Res. 17, 1486-1497 (2002).
26. Zhu, B. et al. Osteopontin modulates CD44-dependent chemotaxis of peritoneal macrophages through G-protein-coupled receptors: Evidence of a role for an intracellular form of osteopontin. J. Cell. Physiol. 198, 155-167 (2004).
27. Wilson, H.L. & O'Neill, H.C. Identification of differentially expressed genes representing dendritic cell precursors and their progeny. Blood 102, 1661-1669 (2003).
28. Renkl, A.C. et al. Osteopontin functionally activates dendritic cells and induces their differentiation toward a Th1-polarizing phenotype. Blood 106, 946-955 (2005).
29. Cantor, H. T-cell receptor crossreactivity and autoimmune disease. Adv. Immunol. 75, 209-233 (2000).
30. Denhardt, D.T., Noda, M., O'Regan, A.W., Pavlin, D. & Berman, J.S. Osteopontin as a means to cope with environmental insults: Regulation of inflammation, tissue remodeling, and cell survival. J. Clin. Invest. 107, 1055-1061 (2001).
31. Diao, H. et al. Osteopontin as a mediator of NKT cell function in T cell-mediated liver diseases. Immunity 21, 539-550 (2004).
32. Weiss, J.M. et al. Osteopontin is involved in the initiation of cutaneous contact hypersensitivity by inducing Langerhans and dendritic cell migration to lymph nodes. J. Exp. Med. 194, 1219-1230 (2001).
33. Szabo, S.J. et al. A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell 100, 655-669 (2000).
34. Lugo-Villarino, G., Ito, S., Klinman, D.M. & Glimcher, L.H. The adjuvant activity of CpG DNA requires T-bet expression in dendritic cells. Proc. Natl. Acad. Sci. USA 102, 13248-13253 (2005).
35. Lugo-Villarino, G., Maldonado-Lopez, R., Possemato, R., Penaranda, C. & Glimcher, L.H. T-bet is required for optimal production of IFN-γ and antigen-specific T cell activation by dendritic cells. Proc. Natl. Acad. Sci. USA 100, 7749-7754 (2003).
36. Hemmi, H., Kaisho, T., Takeda, K. & Akira, S. The roles of Toll-like receptor 9, MyD88, and DNA-dependent protein kinase catalytic subunit in the effects of two distinct CpG DNAs on dendritic cell subsets. J. Immunol. 170, 3059-3064 (2003).
37. Lee, S.W. et al. Effects of a hexameric deoxyriboguanosine run conjugation into CpG oligodeoxynucleotides on their immunostimulatory potentials. J. Immunol. 165, 3631-3639 (2000).
38. Durand, V., Wong, S.Y., Tough, D.F. & Le Bon, A. Shaping of adaptive immune responses to soluble proteins by TLR agonists: A role for IFN-α/ β. Immunol. Cell Biol. 82, 596-602 (2004).
39. Haeryfar, S.M. The importance of being a pDC in antiviral immunity: The IFN mission versus Ag presentation? Trends Immunol. 26, 311-317 (2005).
40. Zuniga, E.I., McGavern, D.B., Pruneda-Paz, J.L., Teng, C. & Oldstone, M.B. Bone marrow plasmacytoid dendritic cells can differentiate into myeloid dendritic cells upon virus infection. Nat. Immunol. 5, 1227-1234 (2004).
41. Baccala, R., Kono, D.H. & Theofilopoulos, A.N. Interferons as pathogenic effectors in autoimmunity. Immunol. Rev. 204, 9-26 (2005).
42. Ballas, Z.K. et al. Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs. J. Immunol. 167, 4878-4886 (2001).
43. Bonifacino, J.S. & Traub, L.M. Signals for sorting of transmembrane proteins to endosomes and lysosomes. Annu. Rev. Biochem. 72, 395-447 (2003).
44. Honda, K. et al. Role of a transductional-transcriptional processor complex involving MyD88 and IRF7 in Toll-like receptor signaling. Proc. Natl. Acad. Sci. USA 101, 15416-15421 (2004).
45. Takaoka, A. et al. Integral role of IRF-5 in the gene induction programme activated by Toll-like receptors. Nature 434, 243-249 (2005).
46. + T lymphocytes by immunostimulatory DNA-based vaccines. J. Immunol. 168, 4907-4913 (2002).
47. Datta, S.K. et al. A subset of Toll-like receptor ligands induces cross-presentation by bone marrow-derived dendritic cells. J. Immunol. 170, 4102-4110 (2003).
48. Heit, A. et al. Cutting edge: Toll-like receptor 9 expression is not required for CpG DNA-aided cross-presentation of DNA-conjugated antigens but essential for cross-priming of CD8 T cells. J. Immunol. 170, 2802-2805 (2003).
49. Barchet, W. et al. Dendritic cells respond to influenza virus through TLR7- and PKR-independent pathways. Eur. J. Immunol. 35, 236-242 (2005).
50. Abel, B., Freigang, S., Bachmann, M. F, Boschert, U. & Kopf, M. Osteopontin is not required for the development of Th1 responses and viral immunity. J. Immunol. 175, 6006-6013 (2005).
51. Hron, J.D. & Peng, S.L. Type I IFN protects against murine lupus. J. Immunol. 173, 2134-2142 (2004).
52. Li, J. et al. Deficiency of type I interferon contributes to Sle2-associated component lupus phenotypes. Arthritis Rheum. 52, 3063-3072 (2005).
53. Baechler, E.C. et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc. Natl. Acad. Sci. USA 100, 2610-2615 (2003).
54. Kono, D.H., Baccala, R. & Theofilopoulos, A.N. Inhibition of lupus by genetic alteration of the interferon-α/β receptor. Autoimmunity 36, 503-510 (2003).
55. Rittling, S.R. et al. Mice lacking osteopontin show normal development and bone structure but display altered osteoclast formation in vitro. J. Bone Miner. Res. 13, 1101-1111 (1998).
56. + cells in mouse lymph nodes and spleen display characteristics of plasmacytoid dendritic cells. J. Exp. Med. 194, 1171-1178 (2001).
57. McCarty, N. et al. Signaling by the kinase MINK is essential in the negative selection of autoreactive thymocytes. Nat. Immunol. 6, 65-72 (2005).
58. Gilliet, M. & Liu, Y.J. Generation of human CD8 T regulatory cells by CD40 ligand-activated plasmacytoid dendritic cells. J. Exp. Med. 195, 695-704 (2002).
59. Hu, D. et al. Analysis of regulatory CD8 T cells in Qa-1-deficient mice. Nat. Immunol. 5, 516-523 (2004).
60. Andrews, N.C. & Faller, D.V. A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells. Nucleic Acids Res. 19, 2499 (1991).